Other News To Note
Thursday, July 12, 2012
Gradalis Inc., of Dallas, signed a collaboration agreement with Baylor College of Medicine for the use of Gradalis' bifunctional shRNA platform for research into therapeutic targets in cancer. Under the agreement, Gradalis will contribute shRNA constructs targeted at specific proteins of interest and access to other technologies, including SuperClean DNA, reversible masking, liposomal delivery and liposomal targeting.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.